Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents
- PMID: 24763265
- DOI: 10.1016/j.ejmech.2014.04.029
Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents
Abstract
A novel series of 6-chloro-2-p-tolylquinazolinone and substituted-(4-methylbenzamido)benzamide (1-20) were designed, synthesized and evaluated for their in-vitro antitumor activity. Compounds 3, 14 and 16 possessed remarkable broad-spectrum antitumor activity. Compound 16 was found to be a particularly active growth inhibitor of the renal cancer (GI50 = 4.07 μM), CNS cancer (GI50 = 7.41 μM), ovarian cancer (GI50 = 7.41 μM) and non-small cell lung cancer (GI50 = 7.94 μM). Compound 16 ranks as nearly 1.5-fold more potent (mean GI50 = 15.8 μM) compared to 5-FU (mean GI50 = 22.6 μM).
Keywords: In-vitro antitumor evaluation; NCI; Quinazoline; Selective activity; Synthesis.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.
Similar articles
-
Design, synthesis and biological evaluation of 2-mercapto-3-phenethylquinazoline bearing anilide fragments as potential antitumor agents: molecular docking study.Bioorg Med Chem Lett. 2013 Jul 1;23(13):3935-41. doi: 10.1016/j.bmcl.2013.04.056. Epub 2013 Apr 29. Bioorg Med Chem Lett. 2013. PMID: 23683592
-
Synthesis and in vitro antitumor activity of substituted quinazoline and quinoxaline derivatives: search for anticancer agent.Eur J Med Chem. 2011 Jun;46(6):2327-46. doi: 10.1016/j.ejmech.2011.03.015. Epub 2011 Mar 15. Eur J Med Chem. 2011. PMID: 21458891
-
Synthesis and in vitro antitumor evaluation of primary amine substituted quinazoline linked benzimidazole.Bioorg Med Chem Lett. 2014 Jan 15;24(2):624-9. doi: 10.1016/j.bmcl.2013.12.005. Epub 2013 Dec 8. Bioorg Med Chem Lett. 2014. PMID: 24360999
-
Novel approaches in the synthesis of batracylin and its analogs: rebirth of an old player?Curr Med Chem. 2012;19(26):4475-87. doi: 10.2174/092986712803251502. Curr Med Chem. 2012. PMID: 22830346 Review.
-
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.Bioorg Med Chem. 2019 Feb 1;27(3):568-577. doi: 10.1016/j.bmc.2018.12.032. Epub 2018 Dec 24. Bioorg Med Chem. 2019. PMID: 30600149 Review.
Cited by
-
Design, synthesis, and carbonic anhydrase inhibition activities of Schiff bases incorporating benzenesulfonamide scaffold: Molecular docking application.Saudi Pharm J. 2023 Dec;31(12):101866. doi: 10.1016/j.jsps.2023.101866. Epub 2023 Nov 10. Saudi Pharm J. 2023. PMID: 38033749 Free PMC article.
-
Synthesis, antitumour activities and molecular docking of thiocarboxylic acid ester-based NSAID scaffolds: COX-2 inhibition and mechanistic studies.J Enzyme Inhib Med Chem. 2018 Dec;33(1):989-998. doi: 10.1080/14756366.2018.1474878. J Enzyme Inhib Med Chem. 2018. PMID: 29806488 Free PMC article.
-
Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.Molecules. 2021 May 18;26(10):2992. doi: 10.3390/molecules26102992. Molecules. 2021. PMID: 34069962 Free PMC article.
-
An insight into the therapeutic potential of quinazoline derivatives as anticancer agents.Medchemcomm. 2017 Apr 7;8(5):871-885. doi: 10.1039/c7md00097a. eCollection 2017 May 1. Medchemcomm. 2017. PMID: 30108803 Free PMC article. Review.
-
Synthesis, potential antitumor activity, cell cycle analysis, and multitarget mechanisms of novel hydrazones incorporating a 4-methylsulfonylbenzene scaffold: a molecular docking study.J Enzyme Inhib Med Chem. 2021 Dec;36(1):1521-1539. doi: 10.1080/14756366.2021.1924698. J Enzyme Inhib Med Chem. 2021. PMID: 34266349 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
